Skip to main content

Most Popular

New ACR RA-ILD Treatment Guidelines – What Were They Smoking!?

Rheumatoid arthritis related interstitial lung disease (RA-ILD) is common, with symptomatic RA-ILD affecting approximately 8% of RA patients. Median survival is around 5 years.

Read Article

FDA Approves Canakinumab for Gout Flares

Medscape
Aug 30, 2023

The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticost

Read Article

A Brief History of Rheumatoid Arthritis Mimics

Sep 06, 2023

Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis (RA) mimics.

Read Article

Infections Rheums Should Worry About

With the increasing development and use of new biologics and oral targeted therapies to treat RA and other immune mediated inflammatory diseases (IMIDs), an awareness of infection risk and prevention has become of increasing interest as well.

Read Article

Hard Conversations: DMARDs and Malignancy

Cancer is the most difficult disease modifying antirheumatic drug (DMARD) risk to discuss with patients.

Read Article

Advice on Multi-Drug Failures in RA

Sep 25, 2023

What’s your next best approach to the rheumatoid arthritis (RA) patient who has failed several DMARDs and biologics?  In such cases you have to either reconsider the diagnosis (especially if seronegative) or reach into your bag of tricks.  

Read Article

SGLT2 Inhibitors as Gout Treatment

MedPage Today
Aug 30, 2023

Patients with gout and type 2 diabetes treated with SGLT2 inhibitors not only had reduced numbers of gout flares, but also lived longer compared with other such patients receiving other medications, researchers said.

Read Article

B Cell Depletion in RA: The future is bright

Sep 04, 2023

The incredible potential of B cell depletion in rheumatic diseases was heralded by its activity in the treatment of rheumatoid arthritis (RA) over 20 years ago. Rituximab (RTX) was cemented into the armamentarium of RA by its efficacy in TNF-inhibitor inadequate responders (REFLEX).

Read Article

Assessing Cardiovascular Risks: The Responsibility of the Rheumatologist

Sep 18, 2023

In 2016, the European League Against Rheumatism (EULAR) posted recommendations for the management of cardiovascular (CV) risks in patients with rheumatoid arthritis (RA) and other inflammatory joint diseases (IJD)1.

Read Article

Update on Anti-Drug Antibodies and Therapeutic Drug Monitoring

Sep 21, 2023

We use biologic agents on a daily basis in the treatment of rheumatoid arthritis (RA). Despite having an expanding array of options, our profession is keen on gaining a deeper understanding of why certain drugs fail and being able to predict the most appropriate next steps in treatment. 

Read Article

Oral Surveillance Changes in Advanced Therapy Use in RA

Sep 06, 2023

The safety of tofacitinib and TNF inhibitors was studied in high risk rheumatoid arthritis (RA) patients in the ORAL Surveillance study, which culminated in an FDA warning in January 2021 on the cardiovascular, cancer and VTE risks associated with JAK inhibitor use.

Read Article

ACR Position Paper: Cost Impact of Rheumatologic Care

Aug 31, 2023

The American College of Rheumatology (ACR) has published evidence that rheumatologic care can save more than $2700 per patient per year.

Read Article

Hard Decisions in RA (9.1.2023)

Sep 01, 2023

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow, and introduces our September campaign - "Hard Decisions in RA".

Read Article

Why aren’t we preventing RA yet?

 Who wouldn’t want to prevent RA?  

Read Article

RheumNow Podcast – with Special Guest Dr. Janet Pope (9.8.2023)

Sep 08, 2023

This week, Dr. Jack Cush reviews the news with special guest, Dr. Janet Pope. They discuss "Not-non-Inferior", large scale genetic screening, Zoster risk w/ newer lupus drugs, tapering, RA referral problems and the TNR webinar session on "ORAL Surveillance Revisited".

Read Article

Respiratory Burden of RA

Sep 13, 2023

Over the last few decades, the availability of biologic and targeted synthetic DMARDs has revolutionized the treatment of RA, resulting in improved mortality and lower likelihood of joint deformities and disability.

Read Article

Hydroxychloroquine Adherence Lowers Cardiovascular Risks

Sep 11, 2023

Daily hydroxychloroquine (HCQ) is better than an apple a day; as a new study shows that adherence to the antimalarial agent significantly lowers future risk of cardiovascular events in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) patients.

Read Article

Woeful Rheumatology Referrals

Sep 07, 2023

Early diagnosis of inflammatory arthritis (IA) is rooted in patient (self or MD) referrals. A recent analysis shows only a minority of rheumatology referrals had inflammatory arthritis, with only 21% were seen within the first 6 weeks of symptoms. 

Read Article

Cardiovascular comorbidity in rheumatoid arthritis

Friday afternoon page: please call to discuss stress test- moderate ischemia. 

Read Article

ICYMI: ACR Guidelines for Interstitial Lung Disease in Patients with Rheumatic Conditions

ACR
Sep 04, 2023

The American College of Rheumatology (ACR) released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Di

Read Article
×